|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
WO2002068579A2
(en)
|
2001-01-10 |
2002-09-06 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
|
GB0120238D0
(en)
|
2001-08-20 |
2001-10-10 |
Univ College Of London |
Sodium channel regulators and modulators
|
|
EP1478656B1
(en)
|
2002-02-01 |
2009-09-16 |
Life Technologies Corporation |
Oligonucleotide compositions with enhanced efficiency
|
|
US7659082B2
(en)
|
2002-02-19 |
2010-02-09 |
Xenon Pharmaceuticals Inc. |
Methods for identifying analgesic agents
|
|
US20040097440A1
(en)
|
2002-11-11 |
2004-05-20 |
Isis Pharmaceuticals Inc. |
Modulation of jumonji expression
|
|
AU2003268096A1
(en)
*
|
2002-08-14 |
2004-03-03 |
Pharmacia Corporation |
ANTISENSE MODULATION OF Nav1.3 EXPRESSION
|
|
EP2305813A3
(en)
|
2002-11-14 |
2012-03-28 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
EP2284269B1
(en)
|
2002-11-18 |
2017-08-09 |
Roche Innovation Center Copenhagen A/S |
Antisense design
|
|
US7341835B2
(en)
|
2004-01-13 |
2008-03-11 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in mouse
|
|
US20050244851A1
(en)
|
2004-01-13 |
2005-11-03 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in human
|
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
|
WO2006047687A2
(en)
|
2004-10-27 |
2006-05-04 |
Schering Corporation |
Compositions and methods for short interfering nucleic acid inhibition of nav1.8
|
|
US20070154896A1
(en)
|
2005-02-11 |
2007-07-05 |
International Business Machines Corporation |
System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
|
|
AU2006311725B2
(en)
|
2005-11-04 |
2011-11-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of NAV1.8 gene
|
|
US8178503B2
(en)
|
2006-03-03 |
2012-05-15 |
International Business Machines Corporation |
Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
|
|
US7901882B2
(en)
|
2006-03-31 |
2011-03-08 |
Affymetrix, Inc. |
Analysis of methylation using nucleic acid arrays
|
|
US20100105134A1
(en)
|
2007-03-02 |
2010-04-29 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
|
WO2009033027A2
(en)
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression of scn9a gene expression and/or function for the treatment of pain
|
|
FR2929292A1
(fr)
|
2008-03-28 |
2009-10-02 |
Exonhit Therapeutics S A Sa |
Procede et methodes de diagnostic de la maladie d'alzheimer
|
|
WO2009143277A2
(en)
*
|
2008-05-20 |
2009-11-26 |
Intradigm Corporation |
Compositions comprising hscn9a sirna and methods of use thereof
|
|
CN109112126B
(zh)
|
2010-06-23 |
2024-06-14 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
|
PT2841578T
(pt)
|
2012-04-23 |
2017-08-10 |
Biomarin Tech Bv |
Resumo
|
|
EP2906255B1
(en)
|
2012-10-12 |
2023-02-22 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
|
AU2014240392A1
(en)
|
2013-03-14 |
2015-11-05 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to Nav1.7
|
|
FR3007656B1
(fr)
|
2013-06-28 |
2015-06-26 |
Galderma Res & Dev |
Modulateurs du canal sodique nav1.9 pour le traitement d'une maladie cutanee inflammatoire et methodes diagnostiques
|
|
EP3169776B1
(en)
|
2014-07-14 |
2025-09-03 |
The Regents of The University of California |
Crispr/cas transcriptional modulation
|
|
GB2547586A
(en)
|
2014-08-20 |
2017-08-23 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof(In the PCT request)
|
|
CN107429250B
(zh)
|
2015-04-03 |
2022-03-01 |
Ionis制药公司 |
用于调节tmprss6表达的化合物和方法
|
|
EP3183347A4
(en)
|
2015-10-17 |
2018-04-18 |
Lifesplice Pharma LLC |
Splice modulating oligonucleotides and methods of use thereof
|
|
US20170319715A1
(en)
|
2016-02-08 |
2017-11-09 |
Circuit Therapeutics, Inc. |
System and method to modulate pain and itch through cutaneous transfer of genetic information
|
|
WO2017209575A1
(en)
|
2016-06-03 |
2017-12-07 |
Seegene, Inc. |
Evaluation of specificity of oligonucleotides
|
|
EP4650364A3
(en)
|
2016-07-06 |
2026-01-21 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
|
EP3481857B1
(en)
|
2016-07-06 |
2026-02-11 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
|
WO2018098328A1
(en)
*
|
2016-11-23 |
2018-05-31 |
Alnylam Pharmaceuticals, Inc. |
Modified rna agents with reduced off-target effect
|
|
US11162104B2
(en)
*
|
2017-01-24 |
2021-11-02 |
Olipass Corporation |
SCN9A antisense pain killer
|
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
CN112513273A
(zh)
|
2018-06-22 |
2021-03-16 |
豪夫迈·罗氏有限公司 |
用于调节scn9a表达的寡核苷酸
|
|
WO2020191241A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
JP2023542889A
(ja)
|
2020-09-17 |
2023-10-12 |
キュー-ステート バイオサイエンシーズ, インコーポレイテッド |
複数の標的を介して疼痛を処置するための治療用組成物
|
|
WO2022232395A2
(en)
|
2021-04-28 |
2022-11-03 |
Q-State Biosciences, Inc. |
Therapeutic compositions for treating pain via multiple targets
|